2. Antibody-drug Conjugate/ADC Related Cell Cycle/DNA Damage
  3. Antibody-Drug Conjugates (ADCs) Antifolate
  4. Mirvetuximab soravtansine (solution)

Mirvetuximab soravtansine (solution)  (Synonyms: IMGN853 (solution))

Cat. No.: HY-132258A Purity: 97.25%
COA
SDS
Handling Instructions Technical Support

Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage.

For research use only. We do not sell to patients.

CAS No. : 1453084-37-1

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Mirvetuximab soravtansine (solution) Related Antibodies

Top Publications Citing Use of Products
Cell Proliferation/Viability Assay
Apoptosis Analysis
Bio/Physico-chemical Assay

    Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287.

    Mirvetuximab soravtansine (MIRV; 1.56-50 nM; 72 h). TCam2_R_SK cisplatin-resistant seminoma cells were treated with increasing doses of MIRV in vitro.

    Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287.

    Mirvetuximab soravtansine (MIRV; 12.5 nM; 0-72 h). Green fluorescent NLG-2102Ep_R_NL cells were cultured, whether alone or in coculture, with red fluorescent NLR-NOY1_R_SK cells with or without 12.5 nM MIRV. The cell number of the green 2102Ep_R_NL cells was evaluated using live-cell imaging in a kinetic proliferation assay.

    Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287.

    Mirvetuximab soravtansine (MIRV; 3.13-12.5 nM; 72 h). Live-cell imaging assays confirmed a significant decrease in the cell number of NLR-JEG3_R_SK choriocarcinoma cells upon treatment with a 3.13nM dose of MIRV.

    Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287.

    Mirvetuximab soravtansine (MIRV; 500 nM; 96 h). Induction of apoptosis via MIRV in cisplatin-resistant NT2_R_SK cells. NT2_R_SK (EC) cells were treated with 500 nM of MIRV or 2.5 µM of CPT in vitro.

    Mirvetuximab soravtansine (solution) purchased from MedChemExpress. Usage Cited in: Cells. 2025 Feb 15;14(4):287.

    Mirvetuximab soravtansine (MIRV; 1.56-50 nM; 72 h). MIRV induced a decrease in cell impedance, as a readout of cytolysis was determined in a kinetic-based impedance assay.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage[1].

    In Vitro

    Mirvetuximab soravtansine (IMGN853; 8 nM; 6 h; IGROV-1 cells) combined with Carboplatin (HY-17393) promotes synergistic growth inhibitory effects and cell cycle perturbations in vitro[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Mirvetuximab soravtansine (solution) Related Antibodies
    In Vivo

    Mirvetuximab soravtansine (IMGN853; 5 mg/kg; i.v.; female severe combined immunodeficient (SCID) mice with patient-derived xenografts) potentiates the antitumor activity of Carboplatin in vivo[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    150000 (average)

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Mirvetuximab soravtansine (solution)]
    Shipping

    Shipping with dry ice.
    Storage

    -80°C, protect from light
    Purity & Documentation

    Purity: 98.20%

    SDS (251 KB)

    COA (232 KB) SEC-HPLC (140 KB)

    Handling Instructions (2659 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Mirvetuximab soravtansine (solution) Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Mirvetuximab soravtansine (solution)1453084-37-1IMGN853 (solution)Antibody-Drug Conjugates (ADCs)AntifolateAntibody-Drug ConjugatesInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Mirvetuximab soravtansine (solution)
    Cat. No.:
    HY-132258A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.